Against the prior comparable 8-K:5.02, the primary document has 6 changed, 1 added, and 10 removed meaningful sentences.
COMPANY OVERVIEW · SOURCE-BACKED
AbbVie Inc.
ABBVCompany evidence profile
Historical market context and recent SEC disclosures for AbbVie Inc. This view uses the current local evidence snapshot.
- Latest adjusted close
- $285.64Observed 2026-10-23
- Return gap vs SPY
- 136.12021-10-25 to 2026-10-23
- Filings in snapshot
- 5Prices 2013-01-02 to 2026-10-23
Price field: vendor-adjusted closeSEC EDGAR company recordCIK 0001551152
THE BRIEF
Start here, then verify below.
Three statements, each labelled by what kind of statement it is. Every number in them is linked to its source further down the page.
Over the selected historical period, ABBV returned 214.4% with a maximum drawdown of -21.9%. These are historical observations, not a forecast.
This local snapshot covers SEC disclosures, latest-restated annual Company Facts when available, and adjusted daily prices. It does not establish valuation, future return, or an investment recommendation.
Generated: deterministic_fallback · Historical observations, not forecasts.
FILED RESULTS
What the latest financial report says
Quarterly figures as filed in the 10-Q for the period ending 2026-06-30, filed 2026-08-03. Read from one filing, so the period and the accounting concept always match the number.
Revenue
+10.2% YoYCurrent: 2026-04-01 — 2026-06-30 · USD
Prior year: $15.42B (2025-04-01 — 2025-06-30)
Reported revenue before expenses; not stock performance.
Category reference unavailable. Only 1 eligible companies; at least 5 are required.
Reference method and sources
As of 2026-08-03. Latest cached filings only; one issuer per CIK (share classes deduplicated); SEC SIC first 3 digits, same annual or quarterly grain, exact accounting concept and currency. Period ends within 45 days, durations within 15 days. Later filings, missing comparisons and zero or loss bases are excluded. Equal-weight median of company YoY rates — not aggregate industry growth, a full industry census, or a matched business peer set.
Metric definition
YoY = current ÷ prior-year value − 1, against the same period a year earlier rather than the previous quarter. Percentage-point gap = company growth − sample median growth.
RevenuesNet income
+285.2% YoYCurrent: 2026-04-01 — 2026-06-30 · USD
Prior year: $0.94B (2025-04-01 — 2025-06-30)
Reported net income after expenses and taxes; the exact SEC concept is below.
Category reference unavailable. Only 1 eligible companies; at least 5 are required.
Reference method and sources
As of 2026-08-03. Latest cached filings only; one issuer per CIK (share classes deduplicated); SEC SIC first 3 digits, same annual or quarterly grain, exact accounting concept and currency. Period ends within 45 days, durations within 15 days. Later filings, missing comparisons and zero or loss bases are excluded. Equal-weight median of company YoY rates — not aggregate industry growth, a full industry census, or a matched business peer set.
Metric definition
YoY = current ÷ prior-year value − 1, against the same period a year earlier rather than the previous quarter. Percentage-point gap = company growth − sample median growth.
NetIncomeLossDiluted EPS
+290.4% YoYCurrent: 2026-04-01 — 2026-06-30 · USD/shares
Prior year: $0.52 / share (2025-04-01 — 2025-06-30)
Diluted earnings per share; not total profit or a growth rate.
Metric definition
YoY = current ÷ prior-year value − 1, against the same period a year earlier rather than the previous quarter. Percentage-point gap = company growth − sample median growth.
EarningsPerShareDilutedConsolidated figures as reported. Accounting treatment and business mix differ between companies, and a filed result is not a forecast.
HISTORY AND RISK
What this has done, and how roughly
Adjusted daily prices over the selected period, against SPY. SPY is an exchange-traded fund tracking the S&P 500.
ABBVSPYAdjusted daily closes
Ending value$31,442From $10,000 invested, 2021-10-25 to 2026-10-23
Return gap vs SPY, in percentage points136.1ABBV +214.4% · SPY +78.4%
Total return+214.4%2021-10-25 to 2026-10-23
Annualised return+25.8%Compound rate over the period shown
Annualised volatility23.4%Daily returns, annualised
Maximum drawdown-21.9%Trough 2022-09-30
Beta to SPY0.29Sensitivity to the benchmark's moves
Correlation with SPY0.211,255 matched sessions
What that felt likeThe worst peak-to-trough fall over this period was -21.9%, and the worst single session was -12.6%. Both already happened; neither bounds what comes next.
Only this section follows the benchmark selector. The brief, filing reactions and Ask evidence stay on SPY; this chart is showing SPY.
Past return and risk are observations about a period that is over. They are not a forecast, and nothing here is investment advice.
PRIMARY DISCLOSURES
What was filed
SEC checked 2026-10-24
The filings themselves, with what the company disclosed kept apart from what this project measured about it.
8-KDirector or principal officer change2026-10-16 00:00+1.9% after filing
- Director or principal officer change
Quoted from the filing
English, as filed
(“AbbVie”) expanded the size of its Board of Directors (the “Board”) from twelve directors to thirteen directors and appointed Dr.
Source passage
English, as filed
Carethers has been appointed to the Public Policy and Sustainability Committee of AbbVie.
Source passage
Against the prior comparable filing
Compared with the filing accepted 2025-05-13: 6 changed, 1 added, 10 removed.
Changed · 91% text match
English, as filed
(“AbbVie”) expanded the size of its Board of Directors (the “Board”) from twelve directors to thirteen directors and appointed Dr.
Changed · 63% text match
English, as filed
Carethers has been appointed to the Public Policy and Sustainability Committee of AbbVie.
8-KResults of operations (earnings)2026-10-06 00:07-0.5% after filing
- Results of operations (earnings)
- Financial statements and exhibits
Quoted from the filing
English, as filed
AbbVie’s full-year 2026 adjusted diluted earnings per share guidance range, including the impact of third-quarter 2026 acquired IPR&D and milestones expense, is $13.76 - $13.96.
Source passage
English, as filed
AbbVie’s third-quarter 2026 adjusted diluted earnings per share guidance range, including the impact of third-quarter 2026 acquired IPR&D and milestones expense, is $3.73 - $3.77.
Source passage
English, as filed
While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions.
Source passage
Numbers in the filing
- $13.76
- $13.96
- $3.73
- $3.77
Against the prior comparable filing
Compared with the filing accepted 2026-07-31: 0 changed, 13 added, 1 removed.
Added
English, as filed
AbbVie’s full-year 2026 adjusted diluted earnings per share guidance range, including the impact of third-quarter 2026 acquired IPR&D and milestones expense, is $13.76 - $13.96.
Added
English, as filed
AbbVie’s third-quarter 2026 adjusted diluted earnings per share guidance range, including the impact of third-quarter 2026 acquired IPR&D and milestones expense, is $3.73 - $3.77.
8-KRegulation FD disclosure2026-09-03 16:47-0.3% after filing
- Regulation FD disclosure
- Financial statements and exhibits
Quoted from the filing
English, as filed
Statements in this Current Report on Form 8-K that are forward-looking may include, but are not limited to, statements regarding AbbVie’s 2026 full-year and third-quarter adjusted diluted EPS guidance, the anticipated benefits of AbbVie’s completed acquisition of Apogee and AbbVie’s ability to successfully integrate Apogee’s operations, employees and pipeline; the expected impact of the acquisition on AbbVie’s adjusted diluted earnings per share; and the anticipated development, regulatory progress and commercial potential of Apogee’s pipeline assets.
Source passage
English, as filed
(the “Company”) issued a press release announcing the completion of its acquisition of Apogee Therapeutics, Inc.
Source passage
English, as filed
AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements.
Source passage
Against the prior comparable filing
Compared with the filing accepted 2026-06-22: 1 changed, 6 added, 13 removed.
Changed · 52% text match
English, as filed
(the “Company”) issued a press release announcing the completion of its acquisition of Apogee Therapeutics, Inc.
Added
English, as filed
Statements in this Current Report on Form 8-K that are forward-looking may include, but are not limited to, statements regarding AbbVie’s 2026 full-year and third-quarter adjusted diluted EPS guidance, the anticipated benefits of AbbVie’s completed acquisition of Apogee and AbbVie’s ability to successfully integrate Apogee’s operations, employees and pipeline; the expected impact of the acquisition on AbbVie’s adjusted diluted earnings per share; and the anticipated development, regulatory progress and commercial potential of Apogee’s pipeline assets.
8-KOther events2026-08-19 00:30+1.9% after filing
- Other events
- Financial statements and exhibits
Quoted from the filing
English, as filed
If AbbVie either (i) publicly announces that the definitive agreement providing for the Acquisition has been terminated prior to the consummation of the Acquisition or (ii) notifies the Trustee in writing that it will not pursue the consummation of the Acquisition, then AbbVie will be required to redeem all of the Floating Rate Notes, 2028 Notes, 2030 Notes, 2031 Notes, 2033 Notes, 2036 Notes and 2038 Notes (but not the 2056 Notes or 2066 Notes) then outstanding at a special mandatory redemption price equal to 101% of the principal amount of such Notes plus accrued and unpaid interest thereon, if any, to, but not including, the special mandatory redemption date.
Source passage
English, as filed
On or after the applicable Par Call Date in respect of a series of Fixed Rate Notes (other than the 2028 Notes), AbbVie may redeem the Fixed Rate Notes of such series, in whole or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the Fixed Rate Notes of such series being redeemed plus accrued and unpaid interest thereon, if any, to, but not including, the redemption date.
Source passage
English, as filed
The Notes Offering was conducted in connection with AbbVie’s previously announced acquisition (the “ Acquisition ”) of Apogee Therapeutics, Inc.
Source passage
Numbers in the filing
- 101%
- 100%
Against the prior comparable filing
Compared with the filing accepted 2026-08-06: 4 changed, 10 added, 18 removed.
Changed · 53% text match
English, as filed
The Notes Offering was conducted in connection with AbbVie’s previously announced acquisition (the “ Acquisition ”) of Apogee Therapeutics, Inc.
Changed · 98% text match
English, as filed
The offering of each series of Notes was registered under the Securities Act of 1933, as amended (the “ Act ”), pursuant to AbbVie’s registration statement on Form S-3ASR (File No. 333-284980) (the “ Registration Statement ”) dated as of February 14, 2025.
8-KOther events2026-08-06 01:17-1.9% after filing
- Other events
- Financial statements and exhibits
Quoted from the filing
English, as filed
The price to the public was 100% of the principal amount for the Floating Rate Notes, 99.970% of the principal amount for the 2028 Notes, 99.862% of the principal amount for the 2030 Notes, 99.977% of the principal amount for the 2031 Notes, 99.889% of the principal amount for the 2033 Notes, 99.832% of the principal amount for the 2036 Notes, 99.810% of the principal amount for the 2038 Notes, 99.441% of the principal amount for the 2056 Notes and 99.843% of the principal amount for the 2066 Notes.
Source passage
English, as filed
The net proceeds from the issuance of the Notes will reduce commitments under AbbVie’s $10.0 billion 364-Day delayed draw term loan facility entered into in connection with the acquisition of Apogee.
Source passage
English, as filed
Factors that could cause actual results or events to differ materially from those anticipated include, but are not limited to, the matters described under Item 1A, “Risk Factors,” and Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in AbbVie’s Annual Report on Form 10-K for the year ended December 31, 2025, which has been filed with the SEC.
Source passage
Numbers in the filing
- 100%
- 99.970%
- 99.862%
- 99.977%
- 99.889%
- 99.832%
- 99.810%
- 99.441%
Against the prior comparable filing
Compared with the filing accepted 2026-03-05: 2 changed, 20 added, 9 removed.
Changed · 59% text match
English, as filed
The foregoing summary of the Notes does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, which is attached as Exhibit 1.1 hereto and is incorporated herein by reference.
Changed · 98% text match
English, as filed
The offering of each series of Notes has been registered under the Securities Act of 1933, as amended (the “ Act ”), pursuant to AbbVie’s registration statement on Form S-3ASR (File No. 333-284980) (the “ Registration Statement ”), dated as of February 14, 2025.
Earlier filings
Each with the move on the first eligible session afterwards, measured against the benchmark. A measurement of magnitude, not a cause.
- 2026-06-22Regulation FD disclosure+0.8% on 2026-06-23Source filing
- 2026-07-07Results of operations (earnings)-0.7% on 2026-07-07Source filing
- 2026-07-31Results of operations (earnings)-3.6% on 2026-08-03Source filing
- 2026-08-06Other events-1.9% on 2026-08-06Source filing
- 2026-08-19Other events+1.9% on 2026-08-19Source filing
- 2026-09-03Regulation FD disclosure-0.3% on 2026-09-04Source filing
- 2026-10-06Results of operations (earnings)-0.5% on 2026-10-06Source filing
- 2026-10-16Director or principal officer change+1.9% on 2026-10-16Source filing
EVENTS AND WHAT IS NEXT
What happened, and what to watch
Event items are published headlines and filing index entries, linked to their source. They are not analysis, and the feed is not a trading signal.
GROUNDED RESEARCH
Ask about this evidence
Questions are answered from this company's evidence packet alone. Citations and number literals are checked against that packet before an answer is shown, and an answer that fails the check is withheld rather than displayed.
No investment advice, price target or directional forecast is produced, and a question asking for one is refused.